Daratumumab for treatment-refractory antibody-mediated diseases in neurology.

Franziska Scheibe Lennard OstendorfHarald PrüssHelena RadbruchTom AschmanSarah HoffmannIgor-Wolfgang BlauChristian MeiselTobias AlexanderAndreas Meisel

Published in: European journal of neurology (2022)

Our findings suggest that daratumumab provided a clinically relevant depletion of autoreactive long-lived plasma cells, identifying plasma cell-targeted therapies as promising escalation therapy for highly active, otherwise treatment-refractory autoantibody-mediated neurological diseases.

Keyphrases

multiple myeloma
induced apoptosis
randomized controlled trial
cell therapy
oxidative stress
cell cycle arrest
cell death
open label
signaling pathway